Topic: How To Invest

Power Growth Investor Hotline – Friday, April 29, 2022

Article Excerpt

BOSTON SCIENTIFIC CORP., $42.11, is a buy. The company (symbol BSX on New York) develops and markets medical devices used in minimally invasive procedures. Its products are used for angioplasty (blood vessel repair), blood clot filtration, cardiac rhythm management, catheter-aided ultrasound imaging, and many other surgical procedures. It generates 58% of its sales in the U.S. and 42% internationally. In the three months ended March 31, 2022, Boston Scientific’s revenues rose 10.0%, to $3.03 billion from $2.75 billion a year earlier. Like other industry suppliers, Boston Scientific was hurt by deferred non-elective surgeries because of the pandemic. However, patient admissions steadily rose during 2021 and into 2022. Excluding one-time items, the company earned $562.0 million, or $0.39 a share, in the quarter. That’s up 7.3% from $524.0 million, or $0.37. The increase was partly the result of higher sales of high-profit-margin products. Lower costs also contributed. Boston Scientific’s outlook is positive. In the past few months, it has gained regulatory approvals for several…